Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013
01 Mai 2013 - 2:00PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company
focused on developing and commercializing inhaled therapies for
patients battling serious lung diseases in orphan indications that
are often life-threatening, today announced that the Company will
release financial results for the three months ended March 31,
2013, before the opening of the stock market on Tuesday, May 7,
2013.
Will Lewis, President and Chief Executive Officer, and Andy
Drechsler, Chief Financial Officer, will host a conference call for
investors beginning at 8:30 a.m. ET on Tuesday, May 7, 2013 to
discuss the first quarter 2013 financial results and to answer
questions.
Shareholders and other interested parties may participate in the
conference call by dialing 888- 803-5993 (domestic) or 706-634-5454
(international) and referencing conference ID number 56371335. The
call will also be broadcast live on the internet on the Company's
website at www.insmed.com.
A replay of the conference call will be accessible two hours
after its completion through May 13, 2013 by dialing 855-859-2056
(domestic) or 404-537-3406 (international) and referencing
conference ID number 56371335. The call will also be archived for
90 days under the Investor Relations section of the Company's
website at www.insmed.com.
About Insmed Insmed Incorporated is a
biopharmaceutical company dedicated to improving the lives of
patients battling serious lung diseases through the development and
commercialization of inhalation therapies in orphan patient
populations with critical unmet needs. Insmed's lead product
candidate, ARIKACE® or liposomal amikacin for inhalation, is
engineered to deliver a proven and potent anti-infective directly
to the site of serious lung infections to improve the efficacy,
safety and convenience of treatment for at least two identified
patient populations: cystic fibrosis (CF) patients with Pseudomonas
aeruginosa lung infections and patients with non-tuberculous
mycobacteria (NTM) lung infections. Insmed's phase 3 registrational
study of ARIKACE in Europe and Canada completed enrollment and the
Company expects top-line clinical results in mid-2013. Insmed's
phase 2 clinical trial in patients with NTM is well under way in
the U.S. and Canada with top-line clinical results expected in late
2013. For more information, please visit http://www.insmed.com.
Forward-Looking Statements This release
contains forward-looking statements that are made pursuant to
provisions of Section 21E of the Securities Exchange Act of 1934.
Words, and variations of words, such as "intend," "expect," "will,"
"anticipate," "believe," "continue," "propose" and similar
expressions are intended to identify forward-looking statements.
Investors are cautioned that such statements in this release,
including statements relating to the status, results and timing of
results of preclinical studies and clinical trials and preclinical
and clinical data and the anticipated benefits of Insmed's
products, constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such risks
and uncertainties include, without limitation, failure or delay of
U.S. Food and Drug Administration and other regulatory reviews and
approvals, competitive developments affecting our product
candidates, delays in product development or clinical trials or
other studies, patent disputes and other intellectual property
developments relating to our product candidates, unexpected
regulatory actions, delays or requests, the failure of clinical
trials or other studies or results of clinical trials or other
studies that do not meet expectations, inability to successfully
develop our product candidates or receive necessary regulatory
approvals, inability to make product candidates commercially
successful, changes in anticipated expenses, and other risks and
challenges detailed in our filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the year ended December 31, 2012. Investors are cautioned not to
place undue reliance on any forward-looking statements that speak
only as of the date of this news release. We undertake no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in our expectations.
Investor Relations Contact: LHA Anne Marie Fields Senior
Vice President 212-838-3777 afields@lhai.com Bruce Voss Managing
Director 310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024